Published 25 September 2024 As of 20 September 2024, the Health Technology Assessment (HTA) Council has completed the evidence appraisal on the assessment of Citicoline for Ischemic Stroke Patients for possible inclusion in the Philippine National Formulary (PNF). As such, the HTA Council hereby makes public its preliminary recommendation on the non-inclusion in the PNF continue reading : [FOR PUBLIC CONSULTATION] HTA Council Preliminary Recommendation on Citicoline For Ischemic Stroke
Insulin Glargine and Insulin Detemir for Type 1 and Type 2 Diabetes Mellitus
On 10 October 2022, the OIC-Secretary of Health (SOH) approved the Health Technology Assessment Council (HTAC) recommendation for the government financing of both insulin glargine 10mL vial (100 IU/ml) and 3mL pre-filled pen (100 IU/ml) for patients with type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) through their inclusion in the Philippine National Formulary (PNF). In continue reading : Insulin Glargine and Insulin Detemir for Type 1 and Type 2 Diabetes Mellitus
Rituximab for the Treatment of Non-Hodgkin’s Lymphoma
Date of publication: 29 July 2022 Approval of the Secretary of health: 31 August 2022 Link to the Evidence summary HTAC Recommendation preview:
Eribulin in the Treatment of Soft Tissue Sarcoma Patients with Previous Treatment of Two Other Chemotherapeutic Agents for Metastatic Disease
Date of publication: 13 June 2022 Approval of the Secretary of health: 09 September 2022 Link to the Evidence summary HTAC RECOMMENDATION PREVIEW:
Lapatinib in the Treatment of HER2-Positive Breast Cancer Patients
Date of publication: May 31, 2021 Evidence Summary: https://drive.google.com/file/d/1VH5tkZyZr9sGWERXk8eXOyIQno456ixT/view Advisory on non-inclusion in PNF: https://drive.google.com/file/d/19PKRWWZ70bKUJBBuKyXnUjCtK01tzEgL/view (Proponents may submit appeals to hta@doh.gov.ph until 14 June 2021.) HTAC Recommendation Review: